abbrevi
use
adenovir
vector
encod
human
chimpanze
adenoviru
develop
oxford
univers
vector
version
ddd
prime
boost
regimen
sequenti
dna
vaccin
ddp
prime
boost
regimen
sequenti
dna
vaccin
follow
protein
vaccin
dipeptidyl
peptidas
cellular
surfac
receptor
protein
merscov
elispot
enzymelink
immunospot
assay
use
evalu
number
antigenspecif
cytokineproduc
cell
merscov
middl
east
respiratori
syndrom
coronaviru
merspp
merscov
pseudotyp
viral
particl
mva
modifi
vaccinia
viru
ankara
nab
neutral
antibodi
nhp
nonhuman
primat
pp
prime
boost
regimen
sequenti
protein
vaccin
rbd
receptorbind
domain
within
subunit
spike
protein
merscov
spike
protein
spike
protein
lack
transmembran
domain
subunit
spike
protein
subunit
spike
protein
sarscov
sever
acut
respiratori
syndrom
coronaviru
vnt
virusneutr
test
middl
east
respiratori
syndrom
coronaviru
merscov
caus
novel
betacoronaviru
isol
late
saudi
arabia
viral
infect
report
human
rang
asymptomat
mild
case
sever
pneumonia
mortal
rate
well
document
dromedari
camel
contract
infect
shed
viru
without
notabl
symptom
anim
infect
least
earli
mechan
camel
human
transmiss
still
clear
sever
primari
case
associ
camel
contact
approv
antivir
drug
vaccin
merscov
despit
activ
research
area
vaccin
candid
develop
use
variou
platform
regimen
test
sever
anim
model
articl
review
publish
studi
merscov
vaccin
focu
vaccin
test
larg
anim
includ
camel
forese
approach
could
best
way
tackl
merscov
endem
arabian
peninsula
use
mass
vaccin
camel
affect
area
block
camel
human
transmiss
camel
vaccin
mortal
rate
mainli
countri
arabian
peninsula
dromedari
camel
strongli
believ
intermedi
host
import
sourc
infect
although
exact
transmiss
mechan
still
unclear
humantohuman
transmiss
document
although
requir
close
lengthi
contact
patient
part
case
mild
asymptomat
fatal
case
result
comorbid
diabet
mellitu
type
preval
arabian
peninsula
asymptomat
case
estim
time
higher
report
case
togeth
mild
case
may
serv
spread
viru
camel
human
primari
case
contact
infect
patient
like
contact
camel
directli
indirectli
howev
camel
believ
intermedi
specul
bat
could
primari
host
dromedari
camel
seroposit
sampl
date
back
earli
african
countri
arabian
peninsula
countri
spanish
canari
island
australian
dromedari
camel
bactrian
camel
sever
group
report
viral
shed
infect
camel
nevertheless
despit
impress
quick
elucid
mani
issu
merscov
gap
understand
emerg
viru
precis
rout
transmiss
cameltohuman
infect
risk
factor
contract
viru
protect
level
neutral
antibodi
nab
importantli
date
specif
antivir
vaccin
treatment
prevent
merscov
infect
articl
review
ongo
effort
vaccin
develop
shed
light
challeng
hinder
progress
speed
develop
merscov
vaccin
merscov
tropism
human
camel
determin
bind
spike
glycoprotein
dipeptidyl
peptidas
surfac
mammalian
cell
respiratori
epitheli
cell
howev
viru
infect
small
experiment
anim
mice
ferret
rat
hamster
mainli
differ
anim
therefor
pose
challeng
develop
vaccin
delay
scientif
investig
viru
infect
pathogen
transmiss
rabbit
model
report
support
merscov
small
anim
model
requir
acceler
merscov
research
therefor
suscept
mous
model
develop
differ
method
first
model
develop
transduc
mice
adenovir
vector
encod
human
deliv
intranas
enabl
mous
cell
respiratori
tract
express
allow
viral
entri
infect
model
easi
use
readili
appli
broad
rang
mous
strain
especi
laboratori
transgen
anim
facil
avail
model
develop
gener
transgen
mice
either
express
human
global
replac
murin
human
ortholog
subject
yet
investig
determin
merscov
replic
upper
respiratori
tract
camel
unlik
human
merscov
infect
affect
mainli
lung
lower
respiratori
tract
result
mild
clinic
manifest
rhinorrhea
experiment
camel
model
infecti
virus
detect
nasal
oropharyng
swab
tissu
day
postinfect
wherea
viral
rna
persist
sampl
month
develop
studi
anim
model
conduct
less
year
acceler
understand
respons
merscov
vaccin
alreadi
test
mous
nhp
camel
model
discuss
section
figur
tabl
although
seem
long
way
go
establish
robust
anim
model
assess
immunogen
efficaci
merscov
vaccin
candid
figur
develop
merscov
vaccin
human
camel
three
vaccin
base
differ
vector
develop
test
plan
test
camel
human
camel
vaccin
could
block
merscov
transmiss
prevent
potenti
outbreak
human
appli
onehealth
concept
vaccin
human
especi
health
care
worker
individu
comorbid
could
prevent
merscov
infect
outbreak
bat
includ
suspect
primari
host
merscov
although
confirm
merscov
spread
infect
camel
naiv
camel
ii
human
may
may
show
symptom
abl
spread
viru
suscept
individu
caus
outbreak
rhesu
macaqu
n
three
differ
regimen
ddd
ddp
pp
interv
protein
dose
induc
strong
rbdspecif
antibodi
week
vaccin
similar
nab
titer
significantli
higher
mockvaccin
monkey
compar
mockvaccin
control
anim
dose
vaccin
reduc
interstiti
infiltr
gross
patholog
lung
anim
challeng
merscov
tabl
vaccin
reduc
viral
rna
load
lung
trachea
tissu
throat
nasal
rectal
swab
sampl
howev
reduct
viral
load
statist
signific
throat
swab
highdos
vaccin
anim
summar
tabl
dose
also
reduc
infecti
viru
titer
lung
trachea
around
moreov
specul
nab
underli
mechan
partial
protect
cellular
respons
test
secret
peripher
blood
monocyt
detect
anim
immun
highest
dose
vaccin
seri
studi
also
conduct
first
defin
minimum
sequenc
merscov
rbd
focu
immun
respons
subunit
vaccin
appeal
found
inactiv
whole
sarscov
use
vaccin
result
enhanc
lung
immunopatholog
vaccin
anim
challeng
sarscov
attribut
presenc
nspecif
antibodi
rather
sspecif
antibodi
therefor
use
whole
antigen
vaccin
could
safe
use
minimum
rbd
fact
studi
report
nab
titer
direct
part
outsid
rbd
boundari
linear
synthes
peptid
correspond
residu
protein
subunit
away
rbd
induc
nab
titer
mice
titer
lower
use
rrbd
synthes
peptid
base
immunoepitop
cellular
immunogen
detect
reagent
avail
camel
subunit
spike
protein
rbd
region
induc
bind
nab
support
use
fulllength
antigen
vaccin
develop
nanoparticl
trimer
protein
produc
vaccin
baculoviru
express
system
use
immun
balbc
mice
alum
matrix
adjuv
latter
induc
significantli
higher
nab
level
higher
alum
moreov
differ
high
low
dose
prime
boost
regimen
separ
studi
antigen
test
mice
differ
form
fulllength
without
transmembran
domain
subunit
form
test
homolog
regimen
mice
prime
boost
regimen
sequenti
dna
vaccin
ddd
prime
boost
regimen
sequenti
protein
vaccin
pp
heterolog
regimen
prime
boost
regimen
sequenti
dna
vaccin
follow
protein
vaccin
ddp
studi
conclud
fulllength
dna
protein
induc
highest
nab
titer
ddp
pp
regimen
note
fulllength
sbase
protein
vaccin
studi
nab
titer
crossprotect
mice
distinct
merscov
isol
could
predict
rbd
sequenc
highli
conserv
isol
studi
also
show
vaccin
fulllength
dna
import
achiev
maxim
neutral
activ
therefor
vaccin
base
full
antigen
test
rhesu
macaqu
use
ddd
pp
ddp
regimen
studi
use
alum
adjuv
proteinbas
vaccin
ddp
follow
tightli
pp
reduc
peak
proport
volum
pulmonari
consolid
measur
comput
tomographi
ct
anim
challeng
merscov
tabl
therefor
seem
regimen
involv
proteinbas
vaccin
superior
dnabas
vaccin
drive
protect
anoth
encourag
studi
also
report
partial
protect
nhp
use
dna
vaccin
base
consensu
sequenc
gene
recombin
mva
encod
fulllength
antigen
use
immun
balbc
mice
via
intramuscular
subcutan
rout
homolog
prime
boost
vaccin
vaccin
base
adenovir
vector
develop
differ
group
use
human
adenoviru
type
first
group
use
vector
encod
either
fulllength
antigen
antigen
immun
balbc
mice
prime
boost
vaccin
intramuscular
rout
prime
intranas
rout
boost
level
similar
antigen
increas
time
boost
peak
level
plateau
week
postboost
similarli
nab
level
doubl
boost
plateau
week
second
group
use
nearli
vaccin
develop
merscov
base
protein
version
induc
nab
howev
elicit
cellular
immun
achiev
vaccin
encod
intern
antigen
nucleocapsid
protein
n
immunoepitop
n
protein
vrp
encod
tcellspecif
epitop
sarscov
nucleocapsid
protein
vrpsarsn
develop
test
balbc
mous
model
vrpsarsn
induc
airway
cell
abl
activ
dendrit
cell
migrat
lymph
node
turn
stimul
epitopespecif
cytotox
cell
result
complet
protect
vaccin
mice
immun
prime
boost
regimen
research
develop
vrpmersn
vaccin
base
n
epitop
analogu
merscov
similar
result
obtain
deplet
airway
cell
inhibit
airway
significantli
decreas
protect
vrpmersn
addit
fact
n
epitop
weak
tcell
epitop
support
role
import
airway
studi
clearli
support
cellular
immun
role
develop
merscov
vaccin
pave
way
toward
panvaccin
univers
encount
exist
potenti
emerg
human
cov
isol
also
use
challeng
summar
tabl
develop
vaccin
human
use
long
process
may
take
decad
take
vaccin
bench
clinic
licensur
given
product
coher
collabor
clinician
scientist
regul
pharmaceut
industri
date
none
test
vaccin
merscov
fail
induc
nab
protect
mice
partial
protect
larg
anim
tabl
viru
seem
polymorph
spike
protein
involv
tropism
cell
entri
contain
neutral
epitop
cost
time
great
extent
make
world
prepar
distribut
vaccin
next
emerg
pathogen
author
thank
prof
sarah
gilbert
univers
oxford
comment
articl
mr
sultan
alharbi
gmailcom
infograph
design
figur
